BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Despite having one of the lowest survival rates of all cancers, there have been no new approved treatments for malignant pleural mesothelioma (MPM) in over a decade. Standard-of-care treatment relies on Cisplatin plus Pemetrexed chemotherapy. Here, we tested a suite of BH3-mimetic drugs targeting BC...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cell Death Discov
Päätekijät: Arulananda, Surein, O’Brien, Megan, Evangelista, Marco, Harris, Tiffany J., Steinohrt, Nikita S., Jenkins, Laura J., Walkiewicz, Marzena, O’Donoghue, Robert J. J., Poh, Ashleigh R., Thapa, Bibhusal, Williams, David S., Leong, Trishe, Mariadason, John M., Li, Xia, Cebon, Jonathan, Lee, Erinna F., John, Thomas, Fairlie, W. D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2020
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7603509/
https://ncbi.nlm.nih.gov/pubmed/33298868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41420-020-00348-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia